Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis

The Journal of Investigative Dermatology
Markus FriedrichKhusru Asadullah

Abstract

The ability of interleukin-10 therapy to reduce the severity of exacerbated psoriasis has been demonstrated recently. Considering the immunobiologic properties of this cytokine we investigated the effects of long-term interleukin-10 application on the immune system and duration of psoriasis remission. We performed a placebo-controlled, double-blind, phase II trial using interleukin-10 in patients with chronic plaque psoriasis in remission. Patients received subcutaneous injections with either interleukin-10 (10 microg per kg body weight; n = 7) or placebo (n = 10) three times per week until relapse or study termination after 4 months. The treatment was well tolerated. In the placebo group almost all patients (90%) showed a relapse during the observation period. In contrast to this, only two of seven patients (28.6%) relapsed in the interleukin-10-treated group. Kaplan-Meier analysis revealed a significantly lower relapse incidence in the interleukin-10 than in the placebo group (p = 0.02). The mean relapse-free interval time was 101.6 +/- 12.6 d in the interleukin-10 group in comparison with 66.4 +/- 10.4 d in the placebo group. Immunologic activity of interleukin-10 application was indicated by an increase in soluble interleuk...Continue Reading

References

Jan 1, 1997·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·G MichelT Ruzicka
Mar 21, 1998·The Journal of Clinical Investigation·K AsadullahW D Döcke
Dec 18, 1998·The Journal of Investigative Dermatology·K ReichC Garbe
Mar 3, 1999·Archives of Dermatology·K AsadullahW Sterry
Jul 20, 1999·Journal of the American Academy of Dermatology·J Koo, M Lebwohl
Jun 16, 2001·The Journal of Investigative Dermatology·K AsadullahW Sterry

❮ Previous
Next ❯

Citations

Jul 2, 2003·Expert Opinion on Investigational Drugs·W I de Boer
Mar 1, 2008·Expert Opinion on Drug Discovery·Christina WeigertKamran Ghoreschi
Jun 4, 2004·Expert Opinion on Biological Therapy·Jane Barry, Brian Kirby
Dec 18, 2015·Science Translational Medicine·Lina SchukurMartin Fussenegger
May 1, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Aldona T PietrzakJacek M Roliński
Dec 22, 2006·Experimental Dermatology·Thomas M ZollnerMichael P Schön
Oct 13, 2006·The Australasian Journal of Dermatology·Michael R Lee, Alan J Cooper
Mar 7, 2009·European Journal of Immunology·Sandra NaundorfGerald Grütz
May 1, 2013·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Ingrid KieranMark Ferguson
May 23, 2014·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Ingrid KieranMark Ferguson
Apr 21, 2004·Journal of the American Academy of Dermatology·Elliot WeissDaniel Nathan Sauder
Jul 2, 2003·Expert Opinion on Investigational Drugs·Jean KanitakisAlain Claudy
Jan 11, 2018·International Journal of Molecular Sciences·Andrea ChiricozziMarco Romanelli
Apr 1, 2018·Experimental Dermatology·Jürgen BrückKamran Ghoreschi
Apr 22, 2006·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Robert P Numerof, Khusru Asadullah
May 30, 2003·Pharmacological Reviews·K AsadullahH D Volk
Mar 18, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jeong-Im WooSung K Moon
Apr 23, 2003·Current Opinion in Rheumatology·Joseph C ShanahanRobert H Carter
Sep 20, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eiko ToichiKevin D Cooper
Jan 4, 2017·Mediators of Inflammation·Priscilla Stela Santana de OliveiraMaira Galdino da Rocha Pitta
Mar 3, 2020·Advances in Wound Care·Emily H SteenSundeep G Keswani
Nov 16, 2005·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Markus FriedrichKhusru Asadullah
Apr 6, 2006·World Journal of Gastroenterology : WJG·Li-Juan Zhang, Xiao-Zhong Wang
Jun 6, 2003·Journal of the American Academy of Dermatology·David James Najarian, Alice B Gottlieb
May 14, 2015·International Journal of Women's Dermatology·Melissa Danesh, Jenny E Murase

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.